过氧化物酶体增殖物激活受体辅调节因子与肾脏损伤的关系  

The relationship between peroxisome proliferator-activated receptors coregulators and kidney injury

作　　者：靳远萌[1] 王伟铭[1] 陈楠[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院肾脏科,上海200025

出　　处：《国际内科学杂志》2007年第9期525-529,共5页International Journal of Internal Medicine

基　　金：国家自然科学基金资助项目(30270613);上海市卫生局重点学科基金(05111001);上海市重点学科(T0201);上海市卫生局重点课题(2003ZD002)

摘　　要：过氧化物酶体增殖物激活受体(PPARs)作为一类核转录因子,能与其特异性配体结合,进而在转录水平上调节多种基因的表达。近年来研究发现,PPARs的辅调节因子,包括辅激活因子和辅抑制因子,能够通过不同的机制促进或抑制PPARs的转录活性,调节其目的基因的表达。并且还是很多细胞内信号通路和翻译后修饰作用的对象,在肾脏疾病的进展中发挥重要重要。选择不同的辅调节因子的激活剂或抑制剂来调节相关基因的转录活性,将会成为治疗一些肾脏疾病如肾小球硬化、肾小球肾炎、糖尿病肾病及肾小管间质疾病的新的治疗手段和方法。Peroxisome proliferator-activated receptors （PPARs） are a group of nuclear transcription factors that regulate many genes expression at mRNA level in a ligand-dependent manner. In recent years, a great of researches certificate that PPARs coregulators, including coactivators and corepressors, can up or down. regulate the transcription activity of PPARs and influence expression of target genes through various mechanisms. Meanwhile, coregulators are also targets of many intracellular signaling transduction pathways and post-translation modification and play important roles in the progression of kidney diseases. Choosing different angonists and antagonists of coregulators to change the transcription activity of disease related genes will lead to novel prevention and treatment strategies of many chronic renal diseases, such as glomerular sclerosis, glomerulonephritis, diabetic nephropathy and tubulointerstitial nephropathy.

关 键 词：过氧化物酶体增殖物激活受体 辅激活因子 辅抑制因子 肾脏损伤 

分 类 号：R692[医药卫生—泌尿科学]